Given the many advances in cell-specific drug delivery over the past decade,10 it is reasonable to envision the development of a therapeutic that targets Nrf2 PPARγ crosstalk within M-MDSCs to treat both acute and CKD. This evidence concerns the gene PPARG and chronic kidney disease.